Our top pick for
Building a portfolio
Predictive Oncology Inc is a medical instruments & supplies business based in the US. Predictive Oncology shares (POAI) are listed on the NASDAQ and all prices are listed in US Dollars. Predictive Oncology employs 22 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$0.63 - $2.30|
|50-day moving average||$1.40|
|200-day moving average||$1.05|
|Wall St. target price||$5.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.43|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$1.3 million|
|Gross profit TTM||$805,080|
|Return on assets TTM||-44.04%|
|Return on equity TTM||-373.14%|
|Market capitalisation||$51.7 million|
TTM: trailing 12 months
There are currently 3.1 million Predictive Oncology shares held short by investors – that's known as Predictive Oncology's "short interest". This figure is 15.9% down from 3.6 million last month.
There are a few different ways that this level of interest in shorting Predictive Oncology shares can be evaluated.
Predictive Oncology's "short interest ratio" (SIR) is the quantity of Predictive Oncology shares currently shorted divided by the average quantity of Predictive Oncology shares traded daily (recently around 2.9 million). Predictive Oncology's SIR currently stands at 1.07. In other words for every 100,000 Predictive Oncology shares traded daily on the market, roughly 1070 shares are currently held short.
However Predictive Oncology's short interest can also be evaluated against the total number of Predictive Oncology shares, or, against the total number of tradable Predictive Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Predictive Oncology's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Predictive Oncology shares in existence, roughly 60 shares are currently held short) or 0.0651% of the tradable shares (for every 100,000 tradable Predictive Oncology shares, roughly 65 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Predictive Oncology.
Find out more about how you can short Predictive Oncology stock.
We're not expecting Predictive Oncology to pay a dividend over the next 12 months.
Predictive Oncology's shares were split on a 1:10 basis on 28 October 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Predictive Oncology shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Predictive Oncology shares which in turn could have impacted Predictive Oncology's share price.
Over the last 12 months, Predictive Oncology's shares have ranged in value from as little as $0.63 up to $2.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Predictive Oncology's is 1.9581. This would suggest that Predictive Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company operates in three segments: Helomics, Soluble, and Skyline. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers STREAMWAY System, a wall-mounted fully automated system that disposes suction fluid providing uninterrupted performance for physicians while virtually eliminating healthcare workers' exposure to infectious fluids collected during surgical and other patient procedures, as well as proprietary cleaning fluid and filters to users of its systems. The company also provides contract research organization (CRO) and AI-driven predictive models of tumor drug response to improve clinical outcomes to assist pharmaceutical, diagnostic, and biotech industries; and soluble and stable formulations for proteins, including vaccines, antibodies, and other protein therapeutics, as well as develops tumor models for precision cancer therapy and drug development. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence (AI) applied to diseases databases.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.